operating loss increased by $ 1.8 million , primarily due to lower profitability in the asia pacific region impacted by lower net sales favorable gross margin and higher sg&a expense.
by region , net sales in both europe and north america achieved significant growth that healthcare has improved in key markets and customers showed strong interest in new products.
importantly , mobility and seating products rebounded strongly at constant currency net sales growth of nearly 18 % in europe and over 12 % in north america.
we continue to see increasing demand for all of our products as evidenced by strong order intake in quote rates and higher than normal backlog.
as a result , in addition to strong sales in the second quarter , demand continues to support elevated order backlog.
starting on slide three , we entered the year with confidence that our second quarter will be a pivotal quarter moving beyond the going to grow revenue.
[ indecipherable ] cash flow to support sales growth during the quarter , usage increased due to higher accounts receivable balances and elevated inventory levels , which kathie will expand on later.
importantly , we expect gross margin to rebound through the remainder of the year.
the continued higher backlog is expected to convert to sales over the next two quarters as we work to fulfill higher demand in the enrolling supply chain disruption.
we view the impact on gross margin is temporary and are taking actions to rectify it.
on the cost side , we saw a good improvement in gross margin from favorable sales mix and the benefit of prior actions to optimize the business.
our operations team is very focused on improving efficiency and costs.
further information can be found in our sec filings.
these were more than offset by supply chain - related disruptions as our factories ended more changeovers and shifting production plans to deal with intermittent part shortages and chipping plays , which accounted for 80 % of the margin decline.
higher material , freight and logistics costs , offset by variable sales is accounted for the other 20 %.
interest in recently launched products in helping invasive customers to provide end users with even more capable devices.
